Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Compass Pathways CEO on Trump's Order to Expand Psychedelics Research
Posted
April 20, 2026
Views
1,831
Likes
34
Comments
19
Engagement
April 20, 2026
1,831
34
19
2.89%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
10:43Now PlayingShares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive order to expedite research and access. US-traded shares of Compass Pathways spiked as much as 53% while AtaiBeckley surged by 37%. GH Research jumped 34% and Definium Therapeutics rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% — touching its highest intraday level since July 2023. The new order directs the US Food and Drug Administration to issue expedited review vouchers to psychedelics with a so-called breakthrough designation, shortening the review time to one to two months from six to ten months. AtaiBeckley, Definium and Compass Pathways all have therapies with breakthrough status. Compass Pathways CEO Kabir Nath joins Bloomberg Businessweek Daily to discuss. He speaks with Carol Massar and Tim Stenovec. Shares of companies involved in psychedelic-tied therapies are surging in Monday trading after President Donald Trump signed an executive order to expedite research and access.
US-traded shares of Compass Pathways Plc spiked as much as 53% while AtaiBeckley Inc. surged by 37%. GH Research PLC jumped 34% and Definium Therapeutics, Inc. rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% — touching its highest intraday level since July 2023. The new order directs the US Food and Drug Administration to issue expedited review vouchers to psychedelics with a so-called breakthrough designation, shortening the review time to one to two months from six to ten months. AtaiBeckley, Definium and Compass Pathways all have therapies with breakthrough status.
For Wall Street, the latest development marks a turning point for the industry that’s long waited for a breakout moment. Analysts see the support for psychedelics from the highest level of the US government as helping to ease the approval pathway for drug developers. he signing of the order is “a substantial step towards diminishing regulatory risk in this emerging class of therapies, enabling investor comfort,” RBC Capital Markets analyst Brian Abrahams wrote in a note to clients. “While not explicitly recommending psychedelics, the nature of the executive order strongly suggests a broad openness to psychedelics.”
Trump’s order also directed the FDA to give new guidance to researchers on ibogaine, a psychedelic compound extracted from the iboga plant in Africa that’s used to treat depression, anxiety and post-traumatic stress disorder for military veterans. While the order doesn’t reclassify the drug for medical use, Trump urged the health professionals to reclassify it quickly.
The order follows an industry setback in 2024 when US regulators rejected an MDMA-assisted therapy for PTSD from Lykos Therapeutics Inc., citing the quality of research and questions over the clinical trial design.
“With several executive branches aligned, investor mindshare should rise meaningfully ahead of potential approvals in 2027-2030,” Jefferies analyst Andrew Tsai wrote in a note.
--------
Watch Bloomberg Radio LIVE on YouTube
Weekdays 7am-6pm ET
Follow us on X
Subscribe to our Podcasts:
Bloomberg Daybreak
Bloomberg Surveillance
Bloomberg Intelligence
Balance of Power
Bloomberg Businessweek
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay
Android Auto
Visit our YouTube channels:
Bloomberg Podcasts
Bloomberg Television
Bloomberg Originals
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
